-

05:51:08 PM

KTTA Stock News

KTTA - Pasithea Therapeutics Corp

06/23/22 9:00 AM

Nasdaq : KTTA

acquisitionlow float

Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC, who together are the largest stockholder of Pasithea Therapeutics Corp., today issued the following statement regarding the Company's dilutive and reactionary acquisition of Alpha-5 integrin, LLC:. Pasithea has already been suffering from significant corporate...

RHEA-AI

negative

06/23/22 8:00 AM

Nasdaq : KTTA, KTTAW

conferenceslow float

Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its

RHEA-AI

neutral

06/22/22 8:00 AM

Nasdaq : KTTA, KTTAW

acquisitionlow float

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases - - Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth - - Closing consideration of 3.26 million shares of Pasithea

RHEA-AI

positive

04/14/22 4:15 PM

Nasdaq : KTTA, KTTAW

conferenceslow float

Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced its Chief

RHEA-AI

neutral

03/30/22 4:15 PM

Nasdaq : KTTA, KTTAW

low float

Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022

RHEA-AI

very positive

03/08/22 8:00 AM

Nasdaq : KTTA, KTTAW

low float

Pasithea Therapeutics Announces Collaboration with The Glimpse Group

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or

RHEA-AI

positive

02/24/22 8:00 AM

Nasdaq : KTTA, KTTAW

low float

Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022

MIAMI BEACH, Fla., Feb.

RHEA-AI

very positive

02/09/22 8:00 AM

Nasdaq : KTTA, KTTAW

managementlow float

Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and

RHEA-AI

neutral

02/03/22 8:00 AM

Nasdaq : KTTA, KTTAW

low float

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and

RHEA-AI

neutral

01/26/22 8:00 AM

Nasdaq : KTTA, KTTAW

low float

Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel

RHEA-AI

neutral